AI Drug Discovery Hits a New Bottleneck: Experimental Validation
Sponsored content brought to you by Artificial intelligence is dramatically accelerating early drug discovery. Models can screen chemical space, predict structures, optimize properties, and propose new molecules at speeds that were unimaginable […] The post AI Drug Discovery Hits a New Bottleneck: Experimental Validation appeared first on GEN - Genetic Engineering and Biotechnology News .
AI-driven drug discovery has reached a new hurdle: validating experimental results to determine if promising candidates are worth pursuing. While artificial intelligence can rapidly generate and screen thousands of potential molecules, the process of testing them in biological systems poses a bottleneck. Derek Chen, senior director of antibody drug discovery at ProBio, explains that the challenge now shifts from creating candidates to identifying the most promising ones that can withstand extensive validation.
This shift in focus necessitates robust experimental capabilities such as high-throughput screening, developability assessment, immunogenicity testing, and advanced in vitro and in vivo studies. AI-generated candidates must still undergo functional screening, safety evaluation, and preclinical testing to confirm their efficacy and compatibility with further development.
Although computational predictions may seem promising, successful medicines must meet a broader set of criteria, including favorable safety, pharmacokinetic properties, and manufacturability. Chen stresses that prioritizing the right candidates based on both strong biological performance and practical attributes is crucial for successful development and commercialization.
To keep pace with AI's rapid candidate generation, companies must invest in technologies that accelerate validation, such as laboratory automation, robotic liquid handling, and advanced assay platforms. The ultimate goal is to create seamless feedback loops where AI-driven design is immediately followed by high-quality experimental data, enabling faster identification of truly valuable drug candidates.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
